Edited for the British Pharmacological Society by C.T. Dollery (Chairman) A. Richens (Secretary) Annmarie Hedges (Press Editor) T.B. Binns A.F. Lant A. Breckenridge G. Mawer W. Watson Buchanan D.G. McDevitt D.B. Caine A.N. Nicholson T. Chard F. O'Grady J. Crooks J.P. Payne D.A.P. Evans B.N.C. Prichard C.F. George M. Rawlins A. Goldberg J. Reid D. Grahame-Smith R.G. Shanks I.W.B. Grant F.O. Simpson R.L. Hodge J.R. Trounce M.H. Lader D.W. Vere O.L. Wade Papers will be considered for publication on all aspects of drug action in man. Manuscripts (two copies) should be sent to Professor A. Richens, Department of Pharmacology and Materia Medica, Welsh National School of Medicine, Heath Park, Cardiff CF4 4XN. The instructions to authors are printed in volume 1 (pages 3 to 6) ofthe journal. Details of the SI symbols for units can be found in the January 1974 issue (volume 50, pages 6 to 23) of the British Journal ofPharmacology. British Journal of Clinical Pharmacology is published monthly by Scientific & Medical Division, Macmillan Publishers Ltd, Houndmills, Basingstoke, Hampshire RG21 2XS. Telephone: Basingstoke 29242. ISSN 0306-5251. Annual subscription: UK £75.00; USA & Canada, US$185; Rest of world, £89; Airmail £102 (or equivalent in any other currency). (Orders must be accompanied by remittance. Prices correct at time of publication.) Cheques should be made payable to Macmillan Journals Limited: Subscription Department, Brunel Road, Basingstoke, Hampshire RG21 2XS, England. Where appropriate, overseas subscribers may make payments into UK Post Office Giro Account No. 519 2455. Full details must accompany the payment. Enquiries concerning advertising space or rates should be addressed to: Advertisement Department, Macmillan Journals Limited, 4 Little Essex Street, London WC2R 3LF. Telephone: 01-836 6633. Copyright ©) 1981 by the British Journal of Clinical Pharmacology. All rights of reproduction are reserved in respect of all papers, articles, illustrations, etc., published in this journal in all countries of the world. Second class postage paid at New York, N.Y. US Mailing Agent: Expediters of the printed Word, Inc., Suite 1217, 527 Madison Ave., New York, N.Y. 10022. INDEX TO VOLUME 11 AUTHOR INDEX A ABEYASEKERA, G. see BRODIE, M.J., 422P ELLIS, A., HALL, J.M., MACIVER, M., ORME, ADDIS, G.J. see BARCLAY, JOYCE, 203 M.I'E. & ROWE, P.H. The in vitro metabolism of AELLIG, W.H. A new technique for recording compliance ethinyloestradiol, mestranol and levonorgestrel by of human hand veins, 237 human jejunal mucosa, 275 AHMAD, R.A. & ROGERS, H.J. Salivary elimination of BACK, D.J. see CRAWFORD, FRANCESCA E., 438P pyrimethamine, 101 BAIRD, G.M., LAWRENCE, J.R., STEELE, W.H. & AITIO, ANTERO see AITIO, MIRJA-LIISA, 279 WILLOUGHBY, M.L.N. Salivary levels of metho- AITIO, MIRJA-LIISA. Plasma concentrations and protein trexate (MTX) as an index of CSF levels in children: a binding of disopyramide and mono-N-dealkyl- pilot study, 112P disopyramide during chronic oral disopyramide therapy, BAKER, J.R., PECK, C.C., RAYBUCK, B.D., OWENS, 369 E.L. & SCHUSTER, B.G. Normal pharmacokinetics of AITIO, MIRJA-LIISA, MANSBURY, LEENA, TALA, doxapram in a patient with renal failure and EERO, HAATAJA, MATTI & AITIO, ANTERO. hypothyroidism, 305 The effect of enzyme induction on the metabolism of BAKKE, O.M. see ASLAKSEN, A., 269 disopyramide in man, 279 BAKRAN, I. jr see PLAVSIC, F., 533 ALBAN DAVIES, H., RHODES, J. & THOMAS, M. BALANT, L. see COCHET, B., 389 Inhibition of gastric acid secretion with mast cell stabil- BALNAVE, K., NEILL, J.D., RUSSELL, C.J., izer, FPL-52694, 53 HARRON, D.W.G., LEAHY, W.J., WILSON, R. & ALBERTI, K.G.M.M. see THOM, S., 423P SHANKS, R.G. Observations on the efficacy and phar- ALLAZ, A.-F. see COCHET, B., 389 macokinetics of betaxolol (SL 75212), a cardioselective ALLEN, MARCIA D. see GREENBLATT, D.J., 35 f-adrenoceptor blocking drug, 171 ALLEN, R. see ORR, M.W., 255 BARBAT, J., WARRINGTON, S.J., WEERASURIYA, ALLONEN, H. see KANTO, J., 629 K. & PATEL, LATA (introduced by TURNER, P.). ALVAN, G., BERGMAN, U. & GUSTAFSSON, L.L. Effect of hydralazine on systolic time intervals, 1 1 7P High unbound fraction of salicylate in plasma during BARBER, H.E., HAWKSWORTH, G.M., PETRIE, J.C., intoxication, 625 RIGBY, J.W., ROBB, O.J. & SCOTT, A.K. Phar- AMESS, J. see TREMBATH, P.W., 19 macokinetics of atenolol and propranolol in young and ANKIER, S.I., MARTIN, B.K., ROGERS, M.S., CAR- elderly subjects, 118P PENTER, P.K. & GRAHAM, C. Trazodone - a new BARBER, H.E., PETERSEN, J. & WHITING, P.H. The assay procedure and some pharmacokinetic parameters, effects of either frusemide or piretanide on the phar- 505 macokinetics of gentamicin, 113P AMICO, A. see MORETTI, A., 511 BARBER, H.E. see WEBSTER, J., 333 ASLAKSEN, A., BAKKE, O.M. & VIGANDER, T. Com- BARBIERI, R., CALDARA, R. & FERRARI, C. Clinical parative pharmacokinetics of theophylline and pharmacology of prazosin: further discussion, 314 aminophylline in man, 269 BARCHOWSKY, A. see ROUTLEDGE, P.A., 245 AUSTIN, K.L., STAPLETON, J.V. & MATHER, L.E. BARCLAY, JOYCE, WHITING, B., MEREDITH, P.A. Pethidine clearance during continuous intravenous infu- & ADDIS, G.J. Theophylline-salbutamol interaction: sions in postoperative patients, 25 bronchodilator response to salbutamol at maximally AWADZI, K., BELL, D.R., BRECKENRIDGE, A.M., effective plasma theophylline concentrations, 203 GILLIES, H.M., HADDOCK, D.R. & ORME, M.l'E. BARNABA, A. see FURLANUT, M., 393 The effect of indomethacin, prednisone and cyprohep- BARNETT, D.B., DAVIES, A.T. & DESAI, N. Differen- tadine in suppressing the adverse reactions following the tial effect of diazepam on short term memory in subjects use of diethylcarbamazine in patients with onchocer- with high or low level anxiety, 41 1P ciasis, 418P BARNETT, D.B., FREEMONT, A.J. & O'MALLEY, B.P. Comparison of plasma levels after conventional and long acting propranolol using a radioreceptor assay, 432P BARTLETT, J. see NEIL-DWYER, G., 549 B BARUZZI, A. see TEDESCHI, G., 618 BATEMAN, D.N. & RAWLINS, M.D. Prazosin BAARS, A.M. see van der KLEUN, E., 85S concentration-effect, metabolism and biological activity BACK, D.J., BATES, M., BRECKENRIDGE, A.M., of metabolites, 221 636 INDEX BATES, M. see BACK, D.J., 275 BROWN, M.J. see JENNER, D.A., 435P BATESON, M.C., FIABANE, A.M., CLARKE, A. & BROWN, K., HODDER, R.W. & NEALE, M.G. Plasma BOUCHIER, I.A.D. Probucol and hypercholes- concentrations of sodium cromoglycate in volunteers terolaemia, 531 determined by a new method, 425P BAXI, A.J. see SHETH, U.K., 251 BRUNNER, D.B., DEPONDS, G., BIOLLAZ, J., KEL- BELAIEFF, J. see COCHET, B., 389 LER, I., BRUNNER, H.R. & SCHELLING, J.L. Effect BELL, D.R. see AWADZI, K., 418P of a new angiotensin converting enzyme inhibitor BELPAIRE, F.M., BOGAERT, M.G., ROSSENEU, M. & MK 421 and its lysine analogue on the components of TEIRLYNCK, 0. Binding of 3-adrenoceptor antagon- the renin system in healthy subjects, 461 ists to human serum albumin, al-acid glycoprotein and BRUNNER, H.R. see BRUNNER, D.B., 461 human serum, 125P BRUNT, P.W. see WEBSTER, J., 333 BENNETT, P.N., DIXON, A.St.J., NOTARIANNI, BUCKINGHAM, JULIA C. Neural mechanisms control- LIDIA J. & OLDHAM, HARRIET G. Paracetamol ling the secretion of corticotrophin releasing factor, 216 metabolism in overdosed patients, 1 1OP BULLOCK, D.W. see REEVES, D.S., 353 BERGMAN, U. see ALVAN, G., 625 BURGESS, C. see HAMER, J., 426P BHATT, ASHA M., PLEUVRY, BARBARA J. & MAD- BYRNE, C. see SALTISSI, S., 497 DISON, STEPHANIE E. Respiratory and metabolic BYWATER, M.J. see REEVES, D.S., 353 effects of oral nefopam in human volunteers, 209 BIANCHETTI, G. see TEDESCHI, G., 430P BIOLLAZ, J. see BRUNNER, D.B., 461 BITT'ENCOURT, P., WADE, P., LLOYD, D., SMITH, C A.T., TOSELAND, P.A. & RICHENS, A. Relation- ship between serum benzodiazepine concentration and CACCIA, C. see MORETTI, A., 511 peak velocity of saccadic eye movements, 437P CALDARA, R. see BARBIERI, R., 314 BLACK, A.K., FINCHAM, N., GREAVES, M.W. & CALVEY, T.N., CHAN, K., DEHGHAN, A. & WIL- HENSBY, C.N. Time course changes in levels of LIAMS, N.E. Kinetics of intravenous pyridostigmine in arachidonic acid and prostaglandins D2, E2, F2C,, and man, 406 6-oxo-PGF1, in human skin following ultraviolet B CALVEY, T.N., CHAN, K., MILNE, L.A., MURRAY, irradiation, 109P G.R. & WILLIAMS, N.E. Plasma levels and urinary BLACKETT, A.N. see SHARMA, J.N., 433P excretion of phenoperidine and its metabolites in volun- BLAIR, I.A. see BOOBIS, A.R., 419P teer subjects, 124P BLANCK, K.J. see JAHNCHEN, E., 361 CAMPBELL, B.C., ELLIOTT, H.L., HUGHES, M.A., BLOOMFIELD, S.S. & HANKS, G.W. The visual MCLEAN, K., MEREDITH, P.A. & REID, J.L. Effect analogue scale, 98 of food on the pharmacokinetics of tolmesoxide in BOELAERT, J. see HALLYNCK, TH., 523 hypertensive patients, 431P BOGAERT, M.G. see BELPAIRE, F.M., 125P CAMPBELL, B.C., REID, J.L. & SHEPHERD, A.N. The BONOLLO, L. see MARTINI, A., 605 effects of captopril on blood pressure, converting en- BONOLLO, L. see MARTINI, A., 611 zyme activity, plasma angiotensin I concentration, renin BONOLLO, L. see MORETTI, A., 511 activity and noradrenaline concentration in normoten- BOOBIS, A.R., BRODIE, M.J., KAHN, G.C., TO- sive sodium replete volunteers, 121 P VERUD, E.-L., BLAIR, I.A., MURRAY, S. & CANNINGS, R., NICHOLSON, A.N. & STONE, BAR- DAVIES, D.S. Comparison of in vivo and in vitro rates BARA M. Contingent negative variation: Studies with a of antipyrine oxidation in man, 419P benzodiazepine, 410P BOOBIS, A.R.